313 related articles for article (PubMed ID: 27721905)
21. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
[TBL] [Abstract][Full Text] [Related]
22. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment.
Drosos AA; Pelechas E; Kaltsonoudis E; Voulgari PV
Curr Rheumatol Rep; 2020 Jun; 22(8):44. PubMed ID: 32591916
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.
Iannone F; Lopalco G; Cantarini L; Galeazzi M; Lapadula G
Clin Rheumatol; 2016 Jan; 35(1):19-23. PubMed ID: 26581205
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
[TBL] [Abstract][Full Text] [Related]
27. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
[TBL] [Abstract][Full Text] [Related]
28. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
29. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
30. Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
Koike T
J Orthop Sci; 2015 Nov; 20(6):951-7. PubMed ID: 26404390
[TBL] [Abstract][Full Text] [Related]
31. Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs.
Ozen G; Pedro S; England BR; Mehta B; Wolfe F; Michaud K
ACR Open Rheumatol; 2019 Sep; 1(7):424-432. PubMed ID: 31777822
[TBL] [Abstract][Full Text] [Related]
32. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study.
Dormuth CR; Fisher A; Hudson M; Austin PC; Ernst P; Bresee L; Chateau D; Tamim H; Paterson JM; Lafrance JP; Taylor-Gjevre RM; Platt RW; Canadian Network For Observational Drug Effect Studies Cnodes Investigators
Semin Arthritis Rheum; 2021 Dec; 51(6):1291-1299. PubMed ID: 34462128
[TBL] [Abstract][Full Text] [Related]
33. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE.
Gaujoux-Viala C; Hudry C; Zinovieva E; Herman-Demars H; Flipo RM
Rheumatology (Oxford); 2021 Dec; 61(1):270-280. PubMed ID: 33774669
[TBL] [Abstract][Full Text] [Related]
34. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
35. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.
Kaltsonoudis E; Pelechas E; Voulgari PV; Drosos AA
Semin Arthritis Rheum; 2019 Feb; 48(4):597-602. PubMed ID: 30075990
[TBL] [Abstract][Full Text] [Related]
36. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
37. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
39. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
Doria A; Zavaglia D
Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
